What is Ascendis Pharma AS (ASND) stock price today?

Ascendis Pharma AS (ASND) currently trades at $220.28 per share. The stock has a market capitalization of $13.61B and a P/E ratio of —x.

Is ASND stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Ascendis Pharma AS has a Smart Value Score of 32/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 5/9 and Altman Z-Score is -2.66.

What is Ascendis Pharma AS's revenue and earnings?

Ascendis Pharma AS has trailing twelve-month (TTM) revenue of $720.13M with profit margins of -31.70%. Earnings per share (EPS) is $-4.40.

Is Ascendis Pharma AS financially healthy?

Ascendis Pharma AS's Piotroski F-Score is 5/9 (moderate financial health). The Altman Z-Score of -2.66 places it in the distress.

ASND

Ascendis Pharma AS

NASDAQ: ASND · HEALTHCARE · BIOTECHNOLOGY

$220.28

-0.81% today

Updated 2026-04-29

Market cap

$13.61B

P/E ratio

—

P/S ratio

18.90x

EPS (TTM)

$-4.40

Dividend yield

—

52W range

$151 – $251

Volume

0.7M

Market cap

$13.61B

P/E ratio

—

P/S ratio

18.90x

EPS (TTM)

$-4.40

Dividend yield

—

52W range

$151 – $251

Volume

0.7M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

8.0

Growth

4.3

Quality

2.5

Profitability

5.0

Valuation

C+

5/9

Piotroski F-Score

Moderate

-2.7

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$296.79

+34.73%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

X-Ray snapshot

Strengths

+ Free cash flow $67.37M — positive

+ Revenue growth 42.30% QoQ

Risks

- Altman Z -2.66 — distress zone

- Thin margins at -31.70%

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$51.17M	$266.72M	$363.64M	$691.71M	$720.13M
Net income	$-583.19M	$-481.45M	$-378.08M	$-219.03M	$-33.25M
EPS	—	—	—	—	$-4.40
Free cash flow	$-510.19M	$-469.80M	$-307.62M	$43.62M	$67.37M
Profit margin	-1,139.63%	-180.51%	-103.97%	-31.67%	-31.70%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
ASND	$13.61B	32	8.0	2.5	5.0	4.3	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Ascendis Pharma AS trades at $220.28. Our Smart Value Score of 32/100 indicates the stock is weak. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of -2.66, it sits in the distress. TTM revenue stands at $720.13M. with profit margins at -31.70%.

Frequently asked questions

What is Ascendis Pharma AS's stock price?

Ascendis Pharma AS (ASND) trades at $220.28.

Is Ascendis Pharma AS overvalued?

Smart Value Score 32/100 (Grade F, Strong Sell).

What is the price target of Ascendis Pharma AS (ASND)?

The analyst target price is $296.79, representing +34.7% upside from the current price of $220.28.

What is Ascendis Pharma AS's revenue?

TTM revenue is $720.13M.

Piotroski F-Score?

5/9 — moderate financial health.

Altman Z-Score?

-2.66 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio18.90x

ROE-818.00%

Beta0.49

50D MA$231.28

200D MA$209.75

Shares out0.06B

Float0.06B

Short ratio—

Avg volume0.7M

Performance

1 week-2.10%

1 month-3.69%

3 months-1.64%

YTD+3.30%

1 year—

3 years—

5 years—

Compare

ASND vs LLY →ASND vs JNJ →ASND vs ABBV →Stock screener →